Hofseth BioCare ASA (HBC.OL)
NOK 1.41
(-23.37%)
NOK 1.41
(-23.37%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -70.6 Million NOK | 7.5% |
| 2022 | -97 Million NOK | -10.61% |
| 2021 | -85.56 Million NOK | -32.38% |
| 2020 | -68.28 Million NOK | -24.12% |
| 2019 | -55.49 Million NOK | 6.59% |
| 2018 | -58.5 Million NOK | -769.53% |
| 2017 | 8.53 Million NOK | 107.41% |
| 2016 | -118.53 Million NOK | -59.51% |
| 2015 | -74.28 Million NOK | -71.95% |
| 2014 | -44.59 Million NOK | -18.24% |
| 2013 | -32.51 Million NOK | 28.98% |
| 2012 | -50.02 Million NOK | -131.65% |
| 2011 | -22.62 Million NOK | -68.32% |
| 2010 | -12.82 Million NOK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -11.43 Million NOK | 75.2% |
| 2024 Q1 | -17.47 Million NOK | 55.76% |
| 2023 Q2 | 18.29 Million NOK | 166.35% |
| 2023 Q4 | -39.78 Million NOK | -242.4% |
| 2023 Q3 | -11.62 Million NOK | -163.5% |
| 2023 FY | - NOK | 7.5% |
| 2023 Q1 | -27.58 Million NOK | 3.06% |
| 2022 Q4 | -28.45 Million NOK | -12.83% |
| 2022 Q3 | -25.21 Million NOK | -47.95% |
| 2022 Q2 | -17.04 Million NOK | 35.22% |
| 2022 FY | - NOK | -10.61% |
| 2022 Q1 | -26.31 Million NOK | -3.4% |
| 2021 Q2 | -14.35 Million NOK | 23.65% |
| 2021 Q1 | -18.8 Million NOK | 3.95% |
| 2021 Q3 | -29.04 Million NOK | -102.35% |
| 2021 Q4 | -25.44 Million NOK | 12.4% |
| 2021 FY | - NOK | -32.38% |
| 2020 FY | - NOK | -24.12% |
| 2020 Q1 | -9.95 Million NOK | 58.33% |
| 2020 Q3 | -23.95 Million NOK | -87.6% |
| 2020 Q2 | -12.77 Million NOK | -28.23% |
| 2020 Q4 | -19.57 Million NOK | 18.28% |
| 2019 Q4 | -23.9 Million NOK | -160.63% |
| 2019 Q2 | -8.04 Million NOK | 33.37% |
| 2019 Q1 | -12.07 Million NOK | 30.08% |
| 2019 Q3 | -9.17 Million NOK | -14.02% |
| 2019 FY | - NOK | 6.59% |
| 2018 Q2 | -12.45 Million NOK | 18.18% |
| 2018 FY | - NOK | -769.53% |
| 2018 Q1 | -15.22 Million NOK | -108.79% |
| 2018 Q4 | -17.26 Million NOK | -27.26% |
| 2018 Q3 | -13.56 Million NOK | -8.93% |
| 2017 Q3 | -6.21 Million NOK | 53.35% |
| 2017 FY | - NOK | 107.41% |
| 2017 Q4 | -7.29 Million NOK | -17.39% |
| 2017 Q1 | 35.43 Million NOK | 434.75% |
| 2017 Q2 | -13.31 Million NOK | -137.58% |
| 2016 Q4 | -10.58 Million NOK | 70.48% |
| 2016 FY | - NOK | -59.51% |
| 2016 Q2 | -43.4 Million NOK | -104.98% |
| 2016 Q1 | -21.17 Million NOK | 38.3% |
| 2016 Q3 | -35.84 Million NOK | 17.4% |
| 2015 Q3 | -9.11 Million NOK | 42.32% |
| 2015 Q4 | -34.31 Million NOK | -276.57% |
| 2015 FY | - NOK | -71.95% |
| 2015 Q1 | -12.99 Million NOK | 37.92% |
| 2015 Q2 | -15.8 Million NOK | -21.59% |
| 2014 FY | - NOK | -18.24% |
| 2014 Q4 | -20.93 Million NOK | -232.61% |
| 2014 Q3 | -6.29 Million NOK | -16.65% |
| 2014 Q2 | -5.39 Million NOK | 24.21% |
| 2014 Q1 | -7.11 Million NOK | 15.81% |
| 2013 Q1 | -11.8 Million NOK | 39.81% |
| 2013 Q2 | -10.07 Million NOK | 14.61% |
| 2013 Q3 | -3.48 Million NOK | 65.44% |
| 2013 Q4 | -8.45 Million NOK | -142.75% |
| 2013 FY | - NOK | 28.98% |
| 2012 Q1 | -13.76 Million NOK | -137.5% |
| 2012 Q3 | -6.46 Million NOK | 36.58% |
| 2012 Q4 | -19.6 Million NOK | -203.48% |
| 2012 FY | - NOK | -131.65% |
| 2012 Q2 | -10.18 Million NOK | 25.97% |
| 2011 Q1 | -4.47 Million NOK | 41.81% |
| 2011 Q4 | -5.79 Million NOK | 3.25% |
| 2011 FY | - NOK | -68.32% |
| 2011 Q3 | -5.98 Million NOK | -12.24% |
| 2011 Q2 | -5.33 Million NOK | -19.26% |
| 2010 Q4 | -7.68 Million NOK | -465.56% |
| 2010 FY | - NOK | 0.0% |
| 2010 Q3 | -1.35 Million NOK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Arctic Bioscience AS | -37.78 Million NOK | -86.854% |
| Aqua Bio Technology ASA | -16.56 Million NOK | -326.149% |
| ArcticZymes Technologies ASA | 31.64 Million NOK | 323.113% |
| BerGenBio ASA | -191.8 Million NOK | 63.19% |
| PCI Biotech Holding ASA | -22.22 Million NOK | -217.712% |
| Thor Medical ASA | -6.82 Million NOK | -933.856% |
| Ultimovacs ASA | -214.85 Million NOK | 67.139% |